Leap Therapeutics Accounts Payable

Leap Therapeutics (LPTX) currently reports a accounts payable of $520K as of March 2026. That compares with $6.4M in the prior-year period — down 91.9% year over year. Use the charts on this page to explore Leap Therapeutics's accounts payable history and peer comparisons.

Leap Therapeutics's accounts payable decreased from $6.4M to $520K — a 91.9% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Leap Therapeutics reported $520K in accounts payable as of March 2026. That compares with $6.4M in the prior-year period — down 91.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $520K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Leap Therapeutics, and consider following LPTX for alerts when major investors trade the stock.

Leap Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $520K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LPTX with unrelated industries.